Literature DB >> 20955411

Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.

Marianne T Severinsen, Malene Cramer Engebjerg, Dora Körmendiné Farkas, Annette Østergaard Jensen, Mette Nørgaard, Sean Zhao, Henrik Toft Sørensen.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20955411     DOI： 10.1111/j.1365-2141.2010.08418.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  26 in total

1.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

2.  Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.

Authors:  Hussain R Yusuf; W Craig Hooper; Scott D Grosse; Christopher S Parker; Sheree L Boulet; Thomas L Ortel
Journal:  Thromb Res       Date:  2014-10-22       Impact factor: 3.944

3.  Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.

Authors:  Nicola Vianelli; Francesca Palandri; Nicola Polverelli; Roberto Stasi; Joel Joelsson; Eva Johansson; Marco Ruggeri; Francesco Zaja; Silvia Cantoni; Angelo Emanuele Catucci; Anna Candoni; Enrica Morra; Magnus Björkholm; Michele Baccarani; Francesco Rodeghiero
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

Review 4.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

5.  Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies.

Authors:  Wendy J Langeberg; W Marieke Schoonen; Melissa Eisen; Laurence Gamelin; Scott Stryker
Journal:  Int J Hematol       Date:  2016-03-24       Impact factor: 2.490

6.  In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.

Authors:  Bethan Psaila; James B Bussel; Matthew D Linden; Bracken Babula; Youfu Li; Marc R Barnard; Chinara Tate; Kanika Mathur; Andrew L Frelinger; Alan D Michelson
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

Review 7.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

8.  Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Authors:  Hussain R Yusuf; W Craig Hooper; Michele G Beckman; Qing C Zhang; James Tsai; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 9.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

Review 10.  Fibronectin maintains the balance between hemostasis and thrombosis.

Authors:  Yiming Wang; Heyu Ni
Journal:  Cell Mol Life Sci       Date:  2016-04-21       Impact factor: 9.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.